Argelia Rosillo-de la Torre, Luisa Rocha, Hermelinda Salgado-Ceballos, Perla E. García Casillas and Gabriel Luna-Barcenas Pages 237 - 246 ( 10 )
Background: Pharmacoresistant epilepsy is a disabling neuronal disorder with harmful consequences that impact patient’s quality of life. Although psychiatric comorbidities are frequently present in patients with epilepsy, they are more common in those patients with pharmacoresistant epilepsy. Despite medical advances, the current existing therapeutic strategies for pharmacoresistant seizure control are not available for all patients and/or present disadvantages. Moreover, the conventional drug therapies for psychiatric comorbidities have several adverse effects. Therefore, in this field, nanotechnology arises as a novel tool for transporting drugs to the brain under pathological conditions with high efficiency and low side effects.
Objective: Present an overview of nanotechnology as a novel, efficient and enhanced therapeutic strategy for controlling pharmacoresistant epilepsy and its associated psychiatric comorbidities.
Conclusion: Nanotechnology emerges as a powerful tool for the control and/or treatment of pharmacoresistant epilepsy and its comorbidities in a more efficient and safer way than conventional treatments.
Nanotechnology, Pharmacorresistant epilepsy, Psychiatric comorbidity, Seizures, Side effects.
Calz. Tenorios 235. Col. Granjas Coapa, 14330 at the Department of Pharmacobiology, Center of Research and Advanced Studies, P.O. Box: 22026, Mexico City